# France Gamma Knife Market > France Gamma Knife Market Research Report: Size, Share, Trend Analysis By Disease Indication (Brain Metastasis, Cancer, Arteriovenous Malformation, Trigeminal Neuralgia, Others) and By Anatomy (Head, Neck, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.45% - **2024:** $ 25.09 Million - **2025:** $ 26.46 Million - **2035:** $ 45 Million - **Key Players:** Elekta AB (SE), Accuray Incorporated (US), Varian Medical Systems (US), Brainlab AG (DE), MediTech (US), Shenzhen Huikang Medical Technology Co., Ltd. (CN), Nanjing Jinling Medical Equipment Co., Ltd. (CN), Leksell Gamma Knife (SE) **Report ID:** MRFR/HC/50654-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/france-gamma-knife-market-52412 --- ## Market Summary ## **France Gamma Knife Market Overview** As per MRFR analysis, the France Gamma Knife Market Size was estimated at 13.31 (USD Million) in 2024.The France Gamma Knife Market Industry is expected to grow from 14(USD Million) in 2025 to 35 (USD Million) by 2035. The France Gamma Knife Market CAGR (growth rate) is expected to be around 8.687% during the forecast period (2025 - 2035) **Key France Gamma Knife Market Trends Highlighted** The France Gamma Knife Market is currently experiencing notable advances due to the increased focus on highly advanced treatment options for brain tumors and other neurological conditions. Becoming a pivotal driver in this market is the growing inclination among healthcare facilities to implement non-invasive surgical techniques, which aligns with France's commitment to enhancing treatment efficacy while minimizing recovery time. Furthermore, the collaboration between hospitals and medical device manufacturers is fostering technological innovations and increasing access to Gamma Knife systems across various regions in France.  This trend is further reinforced by government initiatives aimed at integrating cutting-edge technologies into public health systems, ensuring that healthcare providers can utilize the latest equipment to improve patient outcomes.Opportunities in the France Gamma Knife Market lie in expanding applications of Gamma Knife technology beyond traditional uses. Medical professionals are exploring its potential in treating various conditions, which presents new avenues for growth. The rising awareness among patients and healthcare providers about the benefits of such targeted therapies can enhance demand for Gamma Knife procedures.  Additionally, the integration of telemedicine and enhanced patient management systems can streamline treatment processes, offering healthcare providers innovative ways to cater to patient needs effectively. In recent times, there has been a growing trend toward personalized treatment plans in France, where healthcare professionals tailor therapies based on individual patient profiles.This paradigm shift encourages the adoption of advanced tools like Gamma Knife to deliver precise treatments based on specific tumor characteristics.  Moreover, the French healthcare system is adapting to include multidisciplinary approaches in neurosurgery, promoting collaboration between specialists which can lead to optimized outcomes for patients utilizing Gamma Knife technology. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **France Gamma Knife Market Drivers** **Increasing Incidence of Cancer** The France Gamma Knife Market Industry is witnessing significant growth primarily due to the rising incidence of cancer across the nation. According to the French National Cancer Institute, the incidence of all cancers has been steadily increasing, with estimates suggesting a rise to approximately 400,000 new cases annually by 2025. This alarming trend is primarily driven by various factors including an aging population, lifestyle changes, and environmental factors. To advance the awareness and early detection of cancer, the French government has put into place many health programs, which in turn boost the need for more specialized treatments like Gamma Knife radiosurgery. The French Gamma Knife Market Industry is likely to grow further as hospitals and cancer treatment centers purchase new technology to serve the growing number of patients. **Technological Advancements in Radiation Therapy** Technological advancements in radiation therapy have been pivotal in shaping the France Gamma Knife Market Industry. The introduction of systems with enhanced imaging capabilities and precision treatment delivery has allowed for better targeting of tumors while sparing surrounding healthy tissue. According to the latest announcements by the French Society of Radiation Oncology, the integration of Artificial Intelligence and advanced imaging technologies into Gamma Knife systems is expected to improve treatment outcomes and reduce side effects.This technological evolution is likely to attract more healthcare facilities in France to adopt Gamma Knife treatment protocols, thus driving market growth. **Government Support and Funding for Cancer Treatment** Governmental support for cancer treatment in France plays a significant role in the growth of the France Gamma Knife Market Industry. The French government allocates substantial budgets for healthcare, with a focus on oncology services. Recent policy updates indicated an increase in funding for cancer treatment technologies, with specific emphasis on innovative therapies like Gamma Knife radiosurgery in their National Cancer Control Strategy.  This initiative not only enhances access to advanced treatment options for patients but also bolsters the market by encouraging hospitals and clinics to invest in Gamma Knife technology, ensuring its wider availability. **France Gamma Knife Market Segment Insights** **Gamma Knife Market Disease Indication Insights** The France Gamma Knife Market, particularly within the Disease Indication segment, showcases a diverse range of applications critical for the treatment of neurological and oncological disorders. This market primarily addresses conditions such as Brain Metastasis, Cancer, Arteriovenous Malformation, and Trigeminal Neuralgia, each presenting unique therapeutic needs. Brain Metastasis is particularly significant due to the high incidence of secondary brain tumors in cancer patients, making targeted therapies essential for managing disease progression and improving patient outcomes.Gamma Knife's non-invasive radiation capabilities in this area provide a crucial alternative to traditional surgeries, reducing recovery times and hospital stays in France’s healthcare landscape. The Cancer indication necessitates advanced treatment options as it represents a substantial burden on public health, demanding innovative approaches to enhance survival rates while minimizing side effects. Arteriovenous Malformation (AVM), a vascular condition often requiring surgical intervention, benefits from Gamma Knife’s precise and effective management options, opening new avenues for patients who are not suitable candidates for surgery.Trigeminal Neuralgia, characterized by debilitating facial pain, stands as another vital indication where Gamma Knife therapy presents a minimally invasive solution, significantly alleviating pain for patients seeking relief.  Additionally, the 'Others' category encompasses various rare conditions that may not fall under the major indications yet require specialized treatment options, emphasizing the versatility of Gamma Knife technology. This comprehensive segmentation of the France Gamma Knife Market serves to tailor treatment modalities to patient-specific needs while also aligning with trends toward non-invasive intervention methods, ultimately enhancing the quality of patient care and treatment accessibility in the region. The continued growth of the market supports ongoing Research and Development initiatives aimed at further augmenting treatment efficacy and safety profiles across all these indications, ensuring that healthcare professionals are equipped with innovative tools in their battle against complex neurological disorders. The evolving landscape of healthcare in France, underscored by technological advancements and a growing emphasis on patient-centered care, establishes a robust foundation for the Gamma Knife Market, particularly within the Disease Indication segment, as it navigates future challenges and opportunities in the realm of medical technology. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Gamma Knife Market Anatomy Insights** The Anatomy segment of the France Gamma Knife Market is a vital focus area, shaped by the increasing prevalence of neurological disorders and the growing demand for precise non-invasive treatment options. The segment encapsulates various anatomical regions, prominently featuring the Head and Neck, which are crucial in delivering targeted therapies for conditions like brain tumors and vascular malformations. The importance of the Head segment lies in its ability to enhance treatment outcomes for patients with complex intracranial conditions, while the Neck segment addresses challenges linked to tumors and other pathologies in cervical regions. Each of these areas not only showcases a significant contribution to the overall efficacy of Gamma Knife treatments but also embodies the potential for advancements in technology and techniques. In France, healthcare policies are increasingly promoting localized treatments, which further underlines the significance of these anatomical areas within the Gamma Knife Market. The growth of minimally invasive techniques is expected to drive innovation and adoption of Gamma Knife procedures in these regions, reflecting a broader trend towards enhanced patient care and improved surgical precision in France. **France Gamma Knife Market Key Players and Competitive Insights** The France Gamma Knife Market exhibits a dynamic competitive landscape with several players striving for dominance in the field of neurosurgical devices. The market is characterized by its focus on non-invasive treatments, specifically aimed at the management of brain tumors and other neurological disorders. A focus on technological advancements, regulatory compliance, and strategic partnerships is essential in this space. Key market participants are keenly competitive, implementing varied strategic approaches such as enhancing product portfolios, expanding geographical reach, and improving customer service to enhance their market presence and overall performance.  The growing emphasis on patient-centric solutions and increasing awareness of advanced treatment methods are playing important roles in shaping the competitive dynamics within the market.In this competitive landscape, Arinex has established a strong foothold within the France Gamma Knife Market. The company is noted for its expertise in producing advanced medical technologies, specifically tailored to meet the demands for precision and effectiveness in neurosurgery. Arinex stands out due to its dedication to research and development, allowing it to consistently bring innovative solutions to the market.  The company's robust distribution network and partnerships with leading healthcare institutions drive its visibility and accessibility across France, enabling healthcare providers to adopt its Gamma Knife solutions seamlessly. Arinex’s commitment to customer support and training for healthcare professionals further strengthens its position, ensuring that its offerings are effectively utilized in clinical settings.Benvenue Medical is another noteworthy player in the France Gamma Knife Market, recognized for its innovative contributions to neurosurgical interventions.  The company primarily focuses on developing advanced minimally invasive products that are designed to improve patient outcomes while reducing recovery times. Benvenue Medical has solidified its presence in France through strategic collaborations and partnerships, expanding its operational footprint. The strengths of the company lie in its comprehensive product line that includes state-of-the-art Gamma Knife systems tailored for effective brain tumor treatments.  Additionally, Benvenue Medical’s commitment to ongoing clinical research and patient safety protocols enhances its reputation within the French healthcare community. The company's initiative to explore mergers and acquisitions further showcases its strategy to bolster its market position, aiming for sustained growth and enhanced service offerings in the region. **Key Companies in the France Gamma Knife Market Include** **France Gamma Knife Market Industry Developments** The France Gamma Knife Market has experienced significant developments recently. In October 2023, Accuray announced advancements in its CyberKnife system, enhancing precision radiotherapy that may influence Gamma Knife applications in neurosurgery and oncology treatments within France. In addition, Brainlab has partnered with various French health institutions to facilitate training and implementation of their advanced software solutions, promoting a shift towards innovative treatment methodologies. Among notable M&As, in June 2023, Elekta completed its acquisition of a key technology firm to strengthen its position in the gamma knife segment, aiming to integrate innovative techniques and expand its market share in France.  Furthermore, the sector has seen increased investments in Research and Development from companies such as Aesculap and Varian, aligning with France's ongoing initiatives to advance medical technology and improve patient outcomes. The overall market valuation for companies operating in this space reflects a positive trend, driven by heightened demand for non-invasive cancer therapies and an increasing focus on personalized medicine. Collaborations between medical device manufacturers and research institutions are expected to elevate the standard of care in France's healthcare landscape. **France Gamma Knife Market Segmentation Insights** ## Market Drivers ### Supportive Regulatory Environment A supportive regulatory environment in France is fostering growth in the gamma knife market. The French government, along with health authorities, has established frameworks that encourage the adoption of innovative medical technologies. Regulatory bodies are streamlining the approval processes for new gamma knife systems, which facilitates quicker market entry for manufacturers. Additionally, reimbursement policies for gamma knife procedures are becoming more favorable, making these treatments financially accessible to a broader patient population. This regulatory support is likely to enhance the attractiveness of gamma knife technology for healthcare providers, as it aligns with their goals of improving patient care while managing costs. As a result, the gamma knife market is expected to benefit from this conducive regulatory landscape. ### Rising Incidence of Brain Disorders The gamma knife market in France is experiencing growth due to the increasing incidence of brain disorders such as tumors and vascular malformations. According to health statistics, brain tumors account for approximately 2.5% of all cancers diagnosed in the country. This rising prevalence necessitates advanced treatment options, with gamma knife radiosurgery emerging as a preferred choice due to its non-invasive nature and precision. The ability to target tumors with minimal damage to surrounding tissues is particularly appealing in the French healthcare landscape, where patient outcomes are prioritized. As the population ages, the demand for effective treatment modalities is likely to escalate, further driving the gamma knife market. The market is projected to expand as healthcare providers increasingly adopt this technology to enhance patient care and improve survival rates. ### Technological Innovations in Treatment Technological innovations in treatment methodologies are significantly influencing the gamma knife market in France. Continuous advancements in imaging techniques and treatment planning software enhance the precision and effectiveness of gamma knife procedures. For instance, the integration of MRI and CT imaging allows for better tumor localization, which is crucial for successful treatment outcomes. The introduction of new gamma knife models with improved features, such as enhanced dose delivery and patient comfort, is also likely to attract more healthcare facilities to adopt this technology. As hospitals and clinics seek to provide the best possible care, the demand for state-of-the-art gamma knife systems is expected to rise. This trend indicates a robust growth trajectory for the gamma knife market, as technological progress continues to redefine treatment standards. ### Investment in Healthcare Infrastructure Investment in healthcare infrastructure in France is a significant driver for the gamma knife market. The French government has been actively investing in modernizing healthcare facilities, which includes the acquisition of advanced medical technologies. Reports indicate that healthcare spending in France is expected to reach approximately €200 billion by 2025, with a substantial portion allocated to oncology services. This investment is likely to facilitate the integration of gamma knife systems into hospitals and specialized clinics, thereby enhancing treatment accessibility for patients. Furthermore, the establishment of dedicated cancer treatment centers is anticipated to increase the demand for gamma knife procedures, as these facilities aim to provide cutting-edge therapies. Consequently, the gamma knife market is poised for growth as healthcare infrastructure continues to evolve. ### Growing Awareness of Non-Invasive Treatments There is a growing awareness among patients and healthcare professionals in France regarding the benefits of non-invasive treatments, which is positively impacting the gamma knife market. As patients become more informed about their treatment options, they increasingly prefer procedures that minimize recovery time and reduce hospital stays. Gamma knife radiosurgery offers a compelling alternative to traditional surgical methods, as it allows for outpatient treatment with fewer complications. This shift in patient preference is likely to drive demand for gamma knife procedures, as healthcare providers adapt to meet the evolving expectations of their patients. Additionally, educational campaigns and outreach programs by medical associations are contributing to this awareness, further solidifying the gamma knife market's position in the French healthcare system. ## Future Outlook The [Gamma Knife Market](https://www.marketresearchfuture.com/reports/gamma-knife-market-19189) in France is projected to grow at a 5.45% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for non-invasive treatments. **New opportunities:** - Expansion of telemedicine services for remote consultations and follow-ups. - Development of advanced imaging technologies to enhance treatment precision. - Partnerships with healthcare providers for integrated treatment solutions. By 2035, the gamma knife market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Disease Indication: Brain Metastasis (Largest) vs. Trigeminal Neuralgia (Fastest-Growing) In the France gamma knife market, the disease indication segment is predominantly characterized by Brain Metastasis, which holds the largest market share among various indications. Following closely are Cancer and Arteriovenous Malformation, which also contribute significantly to the market. Trigeminal Neuralgia, while currently smaller in share, shows promising trends, positioning itself as an emerging player in this competitive landscape. Market dynamics are influenced by factors such as rising incidences of neurological disorders and increased awareness of advanced treatment options. The growth trends in the France gamma knife market are primarily driven by the expanding application of gamma knife technology in the treatment of brain-related conditions. The increasing prevalence of brain metastasis cases coupled with innovative treatments leading to better patient outcomes is enhancing market growth. Moreover, the rising adoption of non-invasive surgical options is attracting more patients, and technological advancements are setting a course for growth among emerging sectors such as Trigeminal Neuralgia, which is becoming increasingly recognized for its effectiveness in pain management. Brain Metastasis (Dominant) vs. Trigeminal Neuralgia (Emerging) The Brain Metastasis segment remains dominant in the France gamma knife market due to its established treatment protocols and high efficacy in addressing complex cases. Patients suffering from secondary brain tumors frequently rely on gamma knife radiosurgery as a preferred treatment option. On the other hand, Trigeminal Neuralgia is emerging as a significant area of focus, particularly due to the increasing recognition of gamma knife's effectiveness for chronic facial pain relief. This shift indicates growing opportunities for market players to invest in and promote gamma knife technology tailored for conditions previously treated with more invasive procedures. As awareness and acceptance of gamma knife treatments broaden, Trigeminal Neuralgia is becoming an essential area for future growth and development. ### By Anatomy: Head (Largest) vs. Neck (Fastest-Growing) Among the segments in the France gamma knife market, the distribution of market share reveals that the Head segment is the dominant category, capturing the largest portion of the overall market. This segment is primarily sought after due to its application in treating a variety of cranial conditions, making it indispensable in neurosurgery practices. In contrast, the Neck segment, while smaller in market share, is beginning to gain traction due to increasing awareness of its potential benefits in targeting tumors and other issues in the cervical region. Growth trends indicate a significant increase in demand for gamma knife procedures, particularly in the Neck segment, which is rapidly evolving as a preferred option. Factors driving this growth include advancements in technology, enhancing efficacy in treatment, and the rising incidence of neck-related pathologies. As healthcare providers recognize the advantages of non-invasive treatments, the Neck segment is experiencing accelerated acceptance, marking it as the fastest-growing area within the France gamma knife market. Head (Dominant) vs. Neck (Emerging) The Head segment stands out as the dominant player in the market, characterized by its extensive application in treating diverse cranial disorders. Its established track record and familiarity among medical professionals ensure a consistent demand, positioning it as a cornerstone in the France gamma knife market. Conversely, the Neck segment represents an emerging area with recognized potential for treating conditions such as tumors and vascular malformations. Although it currently holds a smaller share, the Neck segment is gaining interest as technological advancements improve treatment precision and patient outcomes. This evolving landscape positions the Neck segment as a targeted area for growth, capturing the attention of healthcare providers looking for innovative non-invasive solutions. ## Competitive Benchmarking The gamma knife market in France is characterized by a competitive landscape that is increasingly shaped by technological advancements and strategic collaborations among key players. The market appears to be driven by a growing demand for non-invasive treatment options for neurological disorders, which has prompted companies to enhance their product offerings and expand their operational capabilities. Notably, Elekta AB (SE) has positioned itself as a leader in this domain, focusing on innovation and the development of advanced radiation therapy solutions. Similarly, Accuray Incorporated (US) emphasizes precision in its treatment technologies, which aligns with the rising trend towards personalized medicine. These strategic focuses collectively contribute to a dynamic competitive environment, where companies are not only vying for market share but also striving to set new standards in patient care.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing their supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players competing for dominance. However, the influence of major companies like Varian Medical Systems (US) and Brainlab AG (DE) is significant, as they leverage their extensive resources and technological expertise to shape market trends and consumer preferences. This competitive structure suggests that while there is room for smaller players, the presence of established firms creates a challenging environment for new entrants. In October Varian Medical Systems (US) announced a strategic partnership with a leading French healthcare provider to enhance the accessibility of its gamma knife technology across the region. This collaboration is expected to facilitate the integration of advanced treatment options into local healthcare systems, thereby improving patient outcomes. The strategic importance of this partnership lies in its potential to expand Varian's market reach while simultaneously addressing the growing demand for innovative treatment solutions in France. In September Brainlab AG (DE) launched a new software platform designed to optimize treatment planning for gamma knife procedures. This technological advancement is likely to enhance the precision and efficiency of treatments, positioning Brainlab as a frontrunner in the market. The introduction of this platform underscores the company's commitment to innovation and reflects a broader trend towards digital transformation within the healthcare sector. In August Elekta AB (SE) unveiled a new training program aimed at healthcare professionals to improve the utilization of gamma knife technology. This initiative not only demonstrates Elekta's dedication to enhancing user competency but also highlights the importance of education in maximizing the effectiveness of advanced medical technologies. By investing in training, Elekta is likely to strengthen its market position and foster long-term relationships with healthcare providers. As of November the gamma knife market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence (AI) into treatment protocols. Strategic alliances among companies are increasingly shaping the competitive landscape, as firms collaborate to leverage each other's strengths. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains. This shift suggests that companies that prioritize research and development, alongside strategic partnerships, will be better positioned to thrive in the evolving market. ## Recent News & Developments The France Gamma Knife Market has experienced significant developments recently. In October 2023, Accuray announced advancements in its CyberKnife system, enhancing precision radiotherapy that may influence Gamma Knife applications in neurosurgery and oncology treatments within France. In addition, Brainlab has partnered with various French health institutions to facilitate training and implementation of their advanced software solutions, promoting a shift towards innovative treatment methodologies. Among notable M&As, in June 2023, Elekta completed its acquisition of a key technology firm to strengthen its position in the gamma knife segment, aiming to integrate innovative techniques and expand its market share in France.  Furthermore, the sector has seen increased investments in Research and Development from companies such as Aesculap and Varian, aligning with France's ongoing initiatives to advance medical technology and improve patient outcomes. The overall market valuation for companies operating in this space reflects a positive trend, driven by heightened demand for non-invasive cancer therapies and an increasing focus on personalized medicine. Collaborations between medical device manufacturers and research institutions are expected to elevate the standard of care in France's healthcare landscape. ## Report Scope | MARKET SIZE 2024 | 25.09(USD Million) | | --- | --- | | MARKET SIZE 2025 | 26.46(USD Million) | | MARKET SIZE 2035 | 45.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.45% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Elekta AB (SE), Accuray Incorporated (US), Varian Medical Systems (US), Brainlab AG (DE), MediTech (US), Shenzhen Huikang Medical Technology Co., Ltd. (CN), Nanjing Jinling Medical Equipment Co., Ltd. (CN), Leksell Gamma Knife (SE) | | Segments Covered | Disease Indication, Anatomy | | Key Market Opportunities | Advancements in precision targeting technologies enhance treatment efficacy in the gamma knife market. | | Key Market Dynamics | Technological advancements and regulatory changes drive growth in the gamma knife market, enhancing treatment options and accessibility. | | Countries Covered | France | ## Frequently Asked Questions **Q: What was the market valuation of the France gamma knife market in 2024?** A: The market valuation of the France gamma knife market was $25.09 Million in 2024. **Q: What is the projected market valuation for the France gamma knife market in 2035?** A: The projected market valuation for the France gamma knife market is $45.0 Million in 2035. **Q: What is the expected CAGR for the France gamma knife market during the forecast period 2025 - 2035?** A: The expected CAGR for the France gamma knife market during the forecast period 2025 - 2035 is 5.45%. **Q: Which companies are the key players in the France gamma knife market?** A: Key players in the France gamma knife market include Elekta AB, Accuray Incorporated, Varian Medical Systems, Brainlab AG, MediTech, Shenzhen Huikang Medical Technology Co., Ltd., Nanjing Jinling Medical Equipment Co., Ltd., and Leksell Gamma Knife. **Q: What are the main disease indications for gamma knife treatments in France?** A: The main disease indications for gamma knife treatments in France include Brain Metastasis, Cancer, Arteriovenous Malformation, Trigeminal Neuralgia, and Others. **Q: What was the market value for Brain Metastasis treatment in 2024?** A: The market value for Brain Metastasis treatment was $5.0 Million in 2024. **Q: What is the projected market value for Cancer treatment by 2035?** A: The projected market value for Cancer treatment is expected to reach $15.0 Million by 2035. **Q: How does the market value for Trigeminal Neuralgia treatment compare to other indications?** A: The market value for Trigeminal Neuralgia treatment was $3.0 Million in 2024, which is lower compared to other indications like Cancer and Brain Metastasis. **Q: What anatomical areas are primarily targeted in the France gamma knife market?** A: The primary anatomical areas targeted in the France gamma knife market include the Head, Neck, and Others. **Q: What was the market value for the Neck anatomical segment in 2024?** A: The market value for the Neck anatomical segment was $8.0 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-gamma-knife-market-52412*